Internal Medicine

3151 questions

Question 1401Question →

An 82-year-old man with advanced Alzheimer dementia is brought to the emergency department from a skilled nursing facility due to progressive lethargy over the past 3 days. The facility staff report that he has been refusing meals and liquids. On examination, temperature is 37.1°C (98.8°F), blood pressure is 98/60 mm Hg, pulse is 112/min, and respiratory rate is 16/min. The patient appears cachectic with profoundly dry mucous membranes and poor skin turgor. His current weight is 60 kg (132 lb).

Laboratory studies show:
Serum sodium: 168 mEq/L
Serum potassium: 4.1 mEq/L
Serum chloride: 129 mEq/L
Serum bicarbonate: 24 mEq/L
Blood urea nitrogen: 56 mg/dL
Serum creatinine: 1.8 mg/dL

Based on an estimated total body water of 50% of his body weight, what is this patient's calculated free water deficit in liters?

Show answer & explanation

Answer: 6

Answer

6
The free water deficit is calculated using the formula: Water Deficit=TBW×(Actual Serum Na+140−1)Water\ Deficit = TBW \times \left(\frac{Actual\ Serum\ Na^+}{140} - 1\right). Given a weight of 6060 kg and an estimated TBW fraction of 50%50\%, the TBW is 3030 L. The actual serum sodium is 168168 mEq/L. Substituting these values into the formula yields: 30×(168140−1)=30×(1.2−1)=30×0.2=630 \times \left(\frac{168}{140} - 1\right) = 30 \times (1.2 - 1) = 30 \times 0.2 = 6 liters. This represents the volume of solute-free water the patient has lost to develop this degree of hypernatremia.

Step-by-Step Solution

1
Calculate the patient's Total Body Water (TBW).
TBW=60×0.50=30TBW = 60 \times 0.50 = 30 L
Free water deficit calculations require an accurate estimate of the patient's baseline TBW, which is typically 50% of lean body weight for elderly men.
2
Set up the free water deficit formula.
Deficit=TBW×(Actual [Na+]Target [Na+]−1)Deficit = TBW \times \left(\frac{Actual\ [Na^+]}{Target\ [Na^+]} - 1\right)
This formula relates the current total body water to the proportional excess of sodium concentration relative to a normal target (140 mEq/L).
3
Substitute the calculated TBW and provided serum sodium values into the formula to find the final deficit.
Deficit=30×(168140−1)=30×(1.2−1)=30×0.2=6Deficit = 30 \times \left(\frac{168}{140} - 1\right) = 30 \times (1.2 - 1) = 30 \times 0.2 = 6 L
This quantifies the exact volume of pure water required to dilute the current total body solute back to a normal serum sodium concentration of 140 mEq/L.

Key Concept

Free water deficit calculation in hypernatremia
Estimated Time:1m 30s
Question 1402Question →

A 65-year-old man with a history of chronic obstructive pulmonary disease (COPD) and type 2 diabetes mellitus is evaluated in the emergency department for progressive fatigue, shortness of breath, and lower extremity tingling over the past 4 weeks. He has not had fever, increased sputum production, or chest pain. Vital signs show a temperature of 37.0 C (98.6 F), blood pressure of 115/75 mmHg, pulse of 112/min, and respiratory rate of 22/min. Pulse oximetry is 94% on room air.

Physical examination reveals pale conjunctivae and a smooth, beefy red tongue. Neurologic examination shows decreased vibratory sensation in the lower extremities bilaterally. Lung auscultation is clear without wheezes or crackles. Heart exam reveals a 2/6 systolic ejection murmur at the left sternal border.

Laboratory results are as follows:

TestResultReference Range
Hemoglobin7.2 g/dL13.5-17.5 g/dL
Mean corpuscular volume (MCV)116 fL80-100 fL
Leukocytes3,100 /mm³4,500-11,000 /mm³
Platelets105,000 /mm³150,000-400,000 /mm³
Sodium138 mEq/L136-145 mEq/L
Chloride112 mEq/L95-105 mEq/L
Bicarbonate16 mEq/L22-28 mEq/L
Blood urea nitrogen18 mg/dL7-18 mg/dL
Creatinine0.9 mg/dL0.6-1.2 mg/dL
TSH2.1 µU/mL0.5-5.0 µU/mL
Free T40.8 ng/dL0.9-2.4 ng/dL

Arterial blood gas on room air shows pH 7.31, PaCO2 32 mmHg, and PaO2 75 mmHg. Peripheral blood smear reveals hypersegmented neutrophils and macro-ovalocytes. Blood cultures drawn 2 days ago in the outpatient clinic are negative.

Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Measure serum vitamin B12 and methylmalonic acid levels

Answer

Measure serum vitamin B12 and methylmalonic acid levels
The patient's presentation of macrocytic anemia (MCV>100MCV > 100 fL), pancytopenia, a smooth beefy red tongue (glossitis), and neurologic deficits (decreased vibratory sensation) is the classic manifestation of Vitamin B12 (cobalamin) deficiency. The neurologic symptoms, caused by subacute combined degeneration of the dorsal columns and lateral corticospinal tracts, are the key distinguishing feature from folate deficiency. The dyspnea and systolic flow murmur are secondary to the severe anemia. The most appropriate next step to confirm this diagnosis is measuring serum vitamin B12 and methylmalonic acid (MMA) levels. MMA is uniquely elevated in B12 deficiency because B12 is a required cofactor for the conversion of methylmalonyl-CoA to succinyl-CoA.

Step-by-Step Solution

1
Analyze the clinical presentation and laboratory results.
The patient presents with progressive fatigue, dyspnea, macrocytic anemia (MCV 116 fL), pancytopenia, and decreased vibratory sensation.
To identify the primary pathophysiological process driving the patient's symptoms.
2
Correlate the hematologic findings with the neurologic exam.
Megaloblastic anemia combined with dorsal column signs (loss of vibratory sensation) strongly indicates Vitamin B12 (cobalamin) deficiency.
Folate deficiency causes identical hematologic changes but does not cause neurologic deficits.
3
Determine the most appropriate diagnostic test.
Measuring serum vitamin B12 and methylmalonic acid (MMA) levels is required to confirm the diagnosis.
MMA is elevated in B12 deficiency but normal in folate deficiency, providing definitive biochemical confirmation.

Key Concept

Vitamin B12 deficiency presents with megaloblastic anemia, pancytopenia, and neurologic deficits (subacute combined degeneration), and is definitively diagnosed by checking serum B12 and methylmalonic acid levels.
Estimated Time:1m 30s
Question 1403Question →

Laboratory evaluation is performed during a routine follow-up visit for a 64-year-old man with a 15-year history of type 2 diabetes mellitus and hypertension. The patient reports feeling generally well and explicitly denies any recent nausea, vomiting, or diarrhea. His current medication regimen consists of metformin, lisinopril, amlodipine, and atorvastatin. Blood pressure is 134/82 mmHg134/82 \text{ mmHg} and pulse is 72/min72/\text{min}.

Laboratory results are as follows:

TestResult
Serum sodium137 mEq/L137 \text{ mEq/L}
Serum potassium5.9 mEq/L5.9 \text{ mEq/L}
Serum chloride110 mEq/L110 \text{ mEq/L}
Serum bicarbonate15 mEq/L15 \text{ mEq/L}
Blood urea nitrogen34 mg/dL34 \text{ mg/dL}
Serum creatinine1.8 mg/dL1.8 \text{ mg/dL}
Blood glucose142 mg/dL142 \text{ mg/dL}

Urinalysis reveals a pH of 5.25.2 and is negative for glucose, ketones, and cellular casts.

Which of the following pathophysiologic mechanisms best explains this patient's current laboratory findings?

Show answer & explanation

Answer: Reduced production of and distal tubular responsiveness to aldosterone

Answer

Reduced production of and distal tubular responsiveness to aldosterone
This patient has a normal anion gap metabolic acidosis (Anion Gap = 137 - (110 + 15) = 12 mEq/L) accompanied by hyperkalemia. This pattern is pathognomonic for Type 4 Renal Tubular Acidosis (RTA). The most common etiology for Type 4 RTA in adults is hyporeninemic hypoaldosteronism due to diabetic nephropathy. Aldosterone normally functions to reabsorb sodium in exchange for potassium and hydrogen ion secretion in the distal tubule and collecting duct. A lack of aldosterone (or resistance to it) leads to retention of both potassium and hydrogen, causing hyperkalemic metabolic acidosis. The patient's use of lisinopril (an ACE inhibitor) further suppresses aldosterone synthesis, exacerbating the condition.

Step-by-Step Solution

1
Calculate the serum anion gap.
Na+−(Cl−+HCO3−)=137−(110+15)=12 mEq/LNa^+ - (Cl^- + HCO_3^-) = 137 - (110 + 15) = 12 \text{ mEq/L}.
To classify the metabolic acidosis as either normal anion gap or high anion gap. A gap of 12 is within the normal range.
2
Assess the serum potassium level in the context of the acid-base disorder.
The patient has hyperkalemia (5.9 mEq/L5.9 \text{ mEq/L}) along with a normal anion gap metabolic acidosis (NAGMA).
Potassium levels help differentiate the causes of NAGMA. Diarrhea and Type 1/2 RTA present with hypokalemia, whereas Type 4 RTA presents with hyperkalemia.
3
Synthesize the clinical history and medication list.
The patient has longstanding diabetes mellitus and is taking lisinopril (an ACE inhibitor).
Diabetic nephropathy classically damages the juxtaglomerular apparatus, reducing renin secretion (hyporeninemic hypoaldosteronism). ACE inhibitors further decrease aldosterone levels, fully explaining the Type 4 RTA presentation.

Key Concept

Hyperkalemic normal anion gap metabolic acidosis (Type 4 RTA) is commonly caused by hyporeninemic hypoaldosteronism due to diabetic nephropathy and exacerbated by ACE inhibitors.
Estimated Time:1m 30s
Question 1404Question →

Match each patient's clinical presentation with the most likely predominant finding on their peripheral blood smear.

Click a left item, then click its matching right item

Items

A 72-year-old man presents with progressive fatigue, early satiety, and massive splenomegaly; his bone marrow aspiration yields a "dry tap".
A 68-year-old man presents with painless cervical lymphadenopathy; laboratory studies show marked leukocytosis with an absolute lymphocytosis composed of small, mature-appearing cells.
A 35-year-old woman presents with altered mental status, fever, elevated creatinine, and severe thrombocytopenia.
A 28-year-old man of Mediterranean descent has asymptomatic microcytic anemia with a normal ferritin level and an elevated hemoglobin A2.

Matches

Show answer & explanation

Answer

Primary myelofibrosis pairs with teardrop cells; Chronic Lymphocytic Leukemia pairs with smudge cells; Thrombotic Thrombocytopenic Purpura pairs with schistocytes; and Beta-thalassemia trait pairs with target cells.
Each peripheral smear finding is classically linked to its corresponding clinical presentation: teardrop cells with bone marrow fibrosis, smudge cells with the fragile lymphocytes of CLL, schistocytes with the microvascular shearing of TTP, and target cells with the hemoglobinopathies like thalassemia.

Step-by-Step Solution

1
Diagnose the underlying hematologic condition presented in each clinical vignette.
Patient 1 has primary myelofibrosis. Patient 2 has chronic lymphocytic leukemia (CLL). Patient 3 has thrombotic thrombocytopenic purpura (TTP). Patient 4 has beta-thalassemia trait.
Recognizing the disease based on clinical and laboratory clues is required to anticipate the peripheral smear findings.
2
Identify the pathognomonic or highly characteristic peripheral blood smear findings associated with each diagnosed condition.
Myelofibrosis features teardrop cells. CLL features smudge cells. TTP features schistocytes. Thalassemia features target cells.
Red blood cell and white blood cell morphology provide critical diagnostic confirmation for these respective diseases.

Key Concept

Pathognomonic peripheral blood smear findings in hematologic disorders
Question 1405Question →

A 72-year-old man is evaluated in the hospital for decreased urine output. He was admitted 3 days ago for an acute exacerbation of heart failure with reduced ejection fraction. His treatment regimen includes intravenous furosemide, lisinopril, carvedilol, and spironolactone. His weight has decreased by 4 kg (8.8 lb) since admission, and his peripheral edema has significantly improved. However, his urine output over the last 12 hours has been only 250 mL.

Vitals:
Blood pressure: 102/60 mm Hg
Heart rate: 94/min

Laboratory results from today:
Serum:
Sodium: 135 mEq/L
Potassium: 4.8 mEq/L
Chloride: 98 mEq/L
Bicarbonate: 28 mEq/L
Blood urea nitrogen: 80 mg/dL
Creatinine: 2.4 mg/dL

Urine:
Sodium: 75 mEq/L
Creatinine: 120 mg/dL
Urea nitrogen: 600 mg/dL

Based on the laboratory findings, what is this patient's calculated fractional excretion of urea (expressed as a percentage)?

Show answer & explanation

Answer: 15

Answer

15
The correct calculation uses the formula FeUrea=Urine Urea Nitrogen×Serum CreatinineSerum BUN×Urine Creatinine×100FeUrea = \frac{\text{Urine Urea Nitrogen} \times \text{Serum Creatinine}}{\text{Serum BUN} \times \text{Urine Creatinine}} \times 100. Plugging in the provided values gives 600×2.480×120×100\frac{600 \times 2.4}{80 \times 120} \times 100, which simplifies to 14409600×100=15%\frac{1440}{9600} \times 100 = 15\%. In a patient receiving loop diuretics (like furosemide), Fractional Excretion of Sodium (FeNa) is falsely elevated due to diuretic-induced natriuresis. Urea handling in the proximal tubule is unaffected by loop diuretics, making FeUrea a much more reliable indicator of prerenal azotemia. A value below 35%35\% supports the diagnosis of prerenal acute kidney injury due to aggressive over-diuresis.

Step-by-Step Solution

1
Identify the clinical context and indication for calculating FeUrea.
The patient has AKI while on furosemide, making FeNa unreliable. FeUrea is indicated.
Loop diuretics inhibit Na+ reabsorption, falsely elevating FeNa even in prerenal states. Urea is reabsorbed proximally, independent of loop diuretics.
2
Recall the Fractional Excretion of Urea formula.
FeUrea=UUrea×PCrPBUN×UCr×100FeUrea = \frac{U_{Urea} \times P_{Cr}}{P_{BUN} \times U_{Cr}} \times 100
Fractional excretion compares the clearance of a substance (urea) to the clearance of creatinine.
3
Extract the correct values from the laboratory panel.
UUreaU_{Urea} = 600 mg/dL, PCrP_{Cr} = 2.4 mg/dL, PBUNP_{BUN} = 80 mg/dL, UCrU_{Cr} = 120 mg/dL
Accurate variable selection is required; distractors like Urine Na and Serum Na must be ignored.
4
Execute the calculation.
600×2.480×120×100=15%\frac{600 \times 2.4}{80 \times 120} \times 100 = 15\%
Mathematical derivation of the fractional excretion percentage.

Key Concept

Fractional Excretion of Urea (FeUrea) is used to differentiate prerenal AKI from acute tubular necrosis in patients on diuretic therapy, where FeNa is often falsely elevated. A FeUrea < 35% indicates a prerenal etiology.
Question 1406Question →

Match each clinical and laboratory presentation with its most likely underlying pathophysiologic mechanism.

Click a left item, then click its matching right item

Items

A 32-year-old woman presents with heavy menses and mucosal petechiae. Labs show a platelet count of 12,000/mm³, normal PT, normal aPTT, and large platelets on peripheral smear without schistocytes.
A 45-year-old man presents with fever, confusion, and petechiae. Labs show a platelet count of 22,000/mm³, normal PT, normal aPTT, abundant schistocytes on smear, and a creatinine of 2.6 mg/dL.
A 28-year-old pregnant woman with abruptio placentae develops diffuse oozing from venipuncture sites. Labs show a platelet count of 45,000/mm³, prolonged PT, prolonged aPTT, and elevated D-dimer.
A 55-year-old man presents with an unprovoked deep vein thrombosis. Labs show a normal platelet count, normal PT, and a prolonged aPTT that fails to correct when his plasma is mixed with normal plasma.

Matches

Show answer & explanation

Answer

Patient 1 matches with IgG autoantibodies (ITP). Patient 2 matches with ADAMTS13 deficiency (TTP). Patient 3 matches with systemic activation of the coagulation cascade (DIC). Patient 4 matches with autoantibodies against phospholipid-binding proteins (Antiphospholipid Syndrome).
Each clinical vignette provides pathognomonic laboratory findings that differentiate these hematologic disorders. ITP is defined by isolated autoantibody-mediated platelet destruction. TTP is driven by uncleaved von Willebrand factor multimers creating platelet microthrombi (normal coags, schistocytes). DIC involves systemic factor consumption (prolonged coags). Lupus anticoagulant acts as an inhibitor, artificially prolonging aPTT while causing thrombosis.

Step-by-Step Solution

1
Analyze the first presentation (isolated severe thrombocytopenia with normal coagulation times and large platelets).
Identified as Immune Thrombocytopenic Purpura (ITP).
The absence of schistocytes rules out microangiopathic processes, and normal PT/aPTT rules out consumptive coagulopathies.
2
Analyze the second presentation (thrombocytopenia, schistocytes, renal injury, neurologic symptoms, and normal coagulation times).
Identified as Thrombotic Thrombocytopenic Purpura (TTP).
The presence of microangiopathic hemolytic anemia with normal coagulation studies points strictly to ADAMTS13 deficiency causing platelet-rich microthrombi.
3
Analyze the third presentation (bleeding diathesis following obstetric complication, thrombocytopenia, prolonged PT/aPTT, and elevated D-dimer).
Identified as Disseminated Intravascular Coagulation (DIC).
Prolongation of both PT and aPTT alongside thrombocytopenia indicates systemic consumption of both coagulation factors and platelets.
4
Analyze the fourth presentation (venous thrombosis with isolated, non-correcting prolonged aPTT).
Identified as Antiphospholipid Syndrome (specifically lupus anticoagulant).
Failure of the aPTT to correct during a mixing study confirms the presence of an inhibitor (rather than a factor deficiency) which paradoxically causes in vivo thrombosis.

Key Concept

Pathophysiology and laboratory differentiation of thrombocytopenia and coagulation disorders
Question 1407Question →

Match each patient's clinical presentation with the most likely rheumatologic diagnosis.

Click a left item, then click its matching right item

Items

A 45-year-old man with chronic hepatitis B presents with postprandial abdominal pain, testicular pain, and a new-onset right foot drop.
A 38-year-old man with severe asthma and chronic rhinosinusitis develops asymmetric neuropathy and palpable purpura. Labs reveal marked peripheral eosinophilia.
A 42-year-old woman presents with recurrent epistaxis, saddle-nose deformity, hemoptysis, and hematuria. Testing is positive for PR3-ANCA.
A 72-year-old woman presents with temporal headache, scalp tenderness, jaw claudication, and amaurosis fugax.

Matches

Show answer & explanation

Answer

Polyarteritis nodosa matches with the hepatitis B patient; Eosinophilic granulomatosis with polyangiitis matches with the asthmatic patient with eosinophilia; Granulomatosis with polyangiitis matches with the PR3-ANCA positive patient with respiratory and renal involvement; Giant cell arteritis matches with the older patient with jaw claudication and visual symptoms.
Each diagnosis is established by recognizing specific syndromic clusters: PAN is associated with Hepatitis B and mesenteric/neurologic involvement; EGPA features asthma and eosinophilia; GPA features upper/lower airway necrosis and glomerulonephritis; GCA features cranial symptoms in older adults.

Step-by-Step Solution

1
Analyze each patient's demographic profile, comorbidities, and pattern of organ involvement.
Identified distinct syndromic clusters for each patient (e.g., asthma/eosinophilia vs. upper/lower respiratory/renal).
Vasculitides are diagnosed clinically by recognizing specific patterns of organ involvement and associated demographic/serologic risk factors.
2
Correlate the identified syndromic clusters with the known pathophysiologic features of specific systemic vasculitides.
Matched each clinical vignette to the corresponding small, medium, or large vessel vasculitis.
Accurate diagnosis dictates the appropriate immunosuppressive therapy and monitoring strategy.

Key Concept

Diagnosis and clinical recognition of systemic vasculitides
Question 1408Question →

A 54-year-old man is evaluated in the intensive care unit for a new-onset fever. He was admitted 6 days ago following a severe motor vehicle collision that resulted in multiple rib fractures and a pulmonary contusion. He required endotracheal intubation and mechanical ventilation on the day of admission. Over the past 24 hours, he has developed a temperature of 38.9∘C38.9^\circ\text{C} (102.0∘F102.0^\circ\text{F}) and requires an increasing fraction of inspired oxygen (FiO2\text{FiO}_2) and positive end-expiratory pressure. Endotracheal suctioning yields thick, purulent secretions. A chest radiograph reveals a new right lower lobe consolidation. His leukocyte count is 16,500/mm316,500/\text{mm}^3. A bronchoalveolar lavage is performed, and he is started on empiric intravenous vancomycin and cefepime. Two days later, his oxygenation has stabilized. The bronchoalveolar lavage fluid cultures grow >104 CFU/mL> 10^4 \text{ CFU/mL} of *Pseudomonas aeruginosa*. The isolate is susceptible to cefepime, piperacillin-tazobactam, and meropenem. No other organisms are isolated. Which of the following is the most appropriate next step in the pharmacologic management of this patient?

Show answer & explanation

Answer: Discontinue vancomycin and continue intravenous cefepime

Answer

Discontinue vancomycin and continue intravenous cefepime.
The correct response demonstrates appropriate antibiotic stewardship by de-escalating empiric broad-spectrum therapy once culture data are available. The patient has ventilator-associated pneumonia (VAP) and was started on empiric vancomycin (for MRSA) and cefepime (for Pseudomonas and other Gram-negatives). Bronchoalveolar lavage cultures definitively isolated *Pseudomonas aeruginosa* susceptible to cefepime, without any growth of MRSA. Therefore, vancomycin should be discontinued to reduce the risk of adverse effects (e.g., acute kidney injury), and cefepime should be continued as targeted, single-agent therapy.

Step-by-Step Solution

1
Evaluate the clinical presentation and initial management.
The patient developed ventilator-associated pneumonia (VAP) and was appropriately started on empiric broad-spectrum coverage for MRSA (vancomycin) and antipseudomonal beta-lactam (cefepime).
Empiric VAP therapy must cover the most common, high-risk nosocomial pathogens based on local antibiograms and patient risk factors.
2
Analyze the culture and susceptibility data.
Cultures grew only *Pseudomonas aeruginosa*, which is fully susceptible to the currently administered cefepime. Notably, no MRSA or other Gram-positive pathogens were isolated.
Definitive antibiotic therapy relies on pathogen identification and susceptibility testing to optimize efficacy and minimize collateral damage.
3
Apply the principles of antibiotic stewardship to modify therapy.
Vancomycin should be discontinued to eliminate unnecessary MRSA coverage, and cefepime can be continued as targeted monotherapy.
De-escalation of empiric broad-spectrum antibiotics to narrower, targeted agents prevents the development of multidrug-resistant organisms and reduces medication-related adverse effects (such as vancomycin-induced acute kidney injury).

Key Concept

In the management of ventilator-associated pneumonia (VAP), empiric broad-spectrum antibiotics should be de-escalated to targeted monotherapy as soon as culture and susceptibility results are available and demonstrate a susceptible pathogen.
Question 1409Question →

An 81-year-old female resident of a skilled nursing facility is currently recovering in the intensive care unit after presenting three days prior with severe distributive shock secondary to a catheter-associated urinary tract infection. On admission, she was hypotensive and tachycardic, and empiric antimicrobial therapy was initiated with intravenous vancomycin and piperacillin-tazobactam. Today, she is hemodynamically stable, off vasopressor support, and her temperature has normalized to 37.1°C (98.8°F). The indwelling urinary catheter was removed on the first day. Both the admission urine and blood cultures have grown *Escherichia coli*. The susceptibility report for the bloodstream isolate is provided below:

Antimicrobial AgentSusceptibility
AmpicillinResistant
CeftriaxoneResistant
CefepimeResistant
Piperacillin-tazobactamSusceptible
GentamicinSusceptible
MeropenemSusceptible

Based on the culture results and the patient's current clinical status, which of the following is the most appropriate definitive pharmacotherapy?

Show answer & explanation

Answer: Monotherapy with intravenous meropenem

Answer

Monotherapy with intravenous meropenem
The patient has an Escherichia coli bloodstream infection with a classic resistance pattern for an Extended-Spectrum Beta-Lactamase (ESBL) producer, evidenced by resistance to ampicillin and advanced-generation cephalosporins (ceftriaxone, cefepime). For ESBL bacteremia, carbapenems (such as meropenem, imipenem, or ertapenem) are the definitive drug of choice. Although piperacillin-tazobactam frequently tests as susceptible in vitro (due to the tazobactam component inhibiting the ESBL enzyme), robust randomized controlled data (such as the MERINO trial) have clearly demonstrated that definitive therapy with piperacillin-tazobactam results in significantly higher 30-day mortality and clinical failure compared to carbapenems in bloodstream infections. Therefore, despite the patient's initial clinical improvement on empiric therapy, the regimen must be escalated to a carbapenem to ensure definitive cure.

Step-by-Step Solution

1
Analyze the antimicrobial susceptibility report.
Identify resistance to 3rd-generation cephalosporins (ceftriaxone) but susceptibility to carbapenems, indicative of an Extended-Spectrum Beta-Lactamase (ESBL) producing E. coli.
Correct identification of the specific resistance mechanism is mandatory to evaluate true in vivo efficacy versus in vitro testing artifacts.
2
Assess the anatomical site and severity of the infection.
The patient has a confirmed bloodstream infection (bacteremia) originating from the urinary tract.
The efficacy of certain antibiotics varies drastically based on whether the infection is localized (e.g., cystitis) or systemic (e.g., bacteremia).
3
Select the definitive antimicrobial agent.
Transition from empiric piperacillin-tazobactam to a targeted carbapenem (meropenem).
Current IDSA guidelines mandate carbapenems for ESBL bacteremia due to established superiority in mortality outcomes over piperacillin-tazobactam.

Key Concept

Carbapenems are the definitive treatment of choice for bloodstream infections caused by ESBL-producing organisms; piperacillin-tazobactam should be avoided in bacteremia even if reported as susceptible in vitro.
Question 1410Question →

A 45-year-old man presents to the clinic with complaints of progressive enlargement of his hands and feet over the past two years, requiring him to buy larger shoes and a new wedding ring. He also reports excessive sweating and recently began snoring loudly at night. On physical examination, he has a prominent jaw, an enlarged nose, and macroglossia. You suspect a growth hormone-secreting pituitary adenoma. Arrange the following steps in the most appropriate chronological sequence for the diagnosis and initial management of this patient's condition.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is: 1) Measurement of IGF-1, 2) Oral glucose suppression test with GH measurement, 3) MRI of the pituitary gland, and 4) Evaluation for transsphenoidal surgery.
The standard diagnostic and management algorithm for suspected acromegaly proceeds in a stepwise fashion from screening to confirmation to localization to treatment. Initial screening is performed with an IGF-1 level, which integrates pulsatile growth hormone secretion over time. If elevated, the diagnosis must be biochemically confirmed using an oral glucose suppression test. Once biochemical excess is definitively proven, a pituitary MRI is obtained to localize the source (typically a somatotroph adenoma). Finally, transsphenoidal surgical resection is the first-line treatment for the vast majority of cases.

Step-by-Step Solution

1
Identify the suspected diagnosis based on the clinical presentation.
The patient's enlarging hands and feet, coarse facial features, and macroglossia strongly suggest acromegaly.
Recognizing the clinical syndrome determines the correct diagnostic pathway.
2
Determine the best initial screening test.
Serum IGF-1 level is selected as the first step.
Growth hormone is secreted in a pulsatile manner, making random measurements unreliable. IGF-1 provides a stable indicator of overall growth hormone excess.
3
Determine the confirmatory diagnostic test.
An oral glucose suppression test is placed second.
Biochemical confirmation of autonomous growth hormone secretion is required before imaging. Normal physiology involves suppression of growth hormone by a glucose load.
4
Select the appropriate imaging modality.
Pituitary MRI is placed third.
Imaging must only follow biochemical confirmation to avoid the misattribution of symptoms to incidental, nonfunctioning pituitary microadenomas.
5
Determine the definitive initial management.
Surgical evaluation is placed last.
Once the adenoma is functionally and anatomically characterized, transsphenoidal surgery is the definitive primary therapy.

Key Concept

The diagnostic workup for acromegaly requires sequential biochemical testing (screening with IGF-1, followed by confirmatory oral glucose suppression testing) prior to anatomical localization with a pituitary MRI.
Question 1411Question →

Match each specific circulating autoantibody with the endocrine disorder it is most classically used to diagnose or evaluate.

Click a left item, then click its matching right item

Items

Thyroid-stimulating immunoglobulins (TSI)
Anti-thyroid peroxidase (anti-TPO) antibodies
Anti-glutamic acid decarboxylase (anti-GAD65) antibodies
Anti-21-hydroxylase antibodies

Matches

Show answer & explanation

Answer

Thyroid-stimulating immunoglobulins match with Graves disease; Anti-thyroid peroxidase antibodies match with Hashimoto thyroiditis; Anti-glutamic acid decarboxylase antibodies match with Type 1 diabetes mellitus; Anti-21-hydroxylase antibodies match with Primary adrenal insufficiency.
Each circulating autoantibody specifically corresponds to the pathogenesis of a distinct endocrine disorder. The pairings correctly link the antibody targets to their respective clinical syndromes.

Step-by-Step Solution

1
Identify the autoantibody responsible for stimulating the thyroid gland.
Thyroid-stimulating immunoglobulins (TSI) are matched with Graves disease.
These antibodies mimic TSH, leading to unregulated hormone production and clinical hyperthyroidism.
2
Identify the primary autoantibody associated with autoimmune hypothyroidism.
Anti-thyroid peroxidase (anti-TPO) antibodies are matched with Hashimoto thyroiditis.
Anti-TPO antibodies indicate immune-mediated thyroid destruction resulting in eventual hypothyroidism.
3
Identify the autoantibody associated with pancreatic beta-cell destruction.
Anti-glutamic acid decarboxylase (anti-GAD65) antibodies are matched with Type 1 diabetes mellitus.
GAD65 is a major autoantigen in the immune destruction of insulin-producing beta cells.
4
Identify the autoantibody linked to autoimmune destruction of the adrenal cortex.
Anti-21-hydroxylase antibodies are matched with Primary adrenal insufficiency.
The 21-hydroxylase enzyme is the primary target in autoimmune adrenalitis (Addison disease).

Key Concept

Many major endocrine disorders are mediated by specific autoimmune processes, which can be clinically identified through distinct circulating autoantibodies.
Question 1412Question →

Match each presentation of calcium, phosphorus, and parathyroid hormone (PTH) laboratory abnormalities with its most likely underlying pathophysiologic diagnosis.

Click a left item, then click its matching right item

Items

Elevated serum calcium, elevated PTH, and decreased serum phosphorus
Decreased serum calcium, decreased PTH, and elevated serum phosphorus
Decreased serum calcium, elevated PTH, elevated serum phosphorus, and normal serum creatinine
Elevated serum calcium, decreased PTH, and decreased serum phosphorus
Decreased serum calcium, elevated PTH, elevated serum phosphorus, and elevated serum creatinine

Matches

Show answer & explanation

Answer

Primary hyperparathyroidism corresponds to high calcium/PTH and low phosphorus. Hypoparathyroidism matches low calcium/PTH and high phosphorus. Pseudohypoparathyroidism presents with low calcium, high phosphorus, high PTH, and normal creatinine. Malignancy (PTHrP) shows high calcium, low PTH, and low phosphorus. CKD shows low calcium, high phosphorus, high PTH, and elevated creatinine.
Each laboratory profile uniquely identifies a specific derangement in the calcium-PTH-vitamin D axis. Primary defects in PTH secretion cause calcium and PTH to move in the same direction. Secondary responses or ectopic mimics cause them to move in opposite directions. Phosphorus typically moves opposite to functional PTH activity on the kidney, except when overt renal failure physically prevents its excretion.

Step-by-Step Solution

1
Evaluate serum calcium and PTH directionality to determine primary versus secondary derangements.
If both move in the same direction, the defect is likely primary to the parathyroid gland (e.g., primary hyperparathyroidism or hypoparathyroidism). If they move in opposite directions, the parathyroid is responding appropriately to a systemic issue.
PTH regulates calcium; normally, low calcium stimulates PTH, and high calcium suppresses PTH.
2
Analyze serum phosphorus levels in relation to PTH.
PTH promotes phosphaturia. Elevated PTH should normally cause low phosphorus (as seen in primary hyperparathyroidism). If PTH is high but phosphorus is also high, suspect renal failure (CKD) or renal resistance to PTH (pseudohypoparathyroidism).
Kidneys are the primary site of phosphate regulation by PTH.
3
Differentiate between pseudohypoparathyroidism and secondary hyperparathyroidism.
Check renal function (creatinine). Elevated creatinine points to CKD, whereas normal creatinine points to pseudohypoparathyroidism.
CKD causes phosphate retention due to loss of glomerular filtration, whereas pseudohypoparathyroidism involves a specific receptor/signaling defect with normal overall renal filtration capacity.

Key Concept

Diagnosis of calcium and parathyroid disorders relies on recognizing the normal physiological feedback loops between serum calcium, serum phosphorus, intact parathyroid hormone, and renal function.
Question 1413Question →

Match each constellation of laboratory findings to the most likely underlying pathophysiologic diagnosis.

Click a left item, then click its matching right item

Items

Calcium 11.2 mg/dL11.2\text{ mg/dL}, Phosphorus 2.2 mg/dL2.2\text{ mg/dL}, Intact PTH 125 pg/mL125\text{ pg/mL}, 24-hour urine calcium 350 mg/day350\text{ mg/day}
Calcium 7.6 mg/dL7.6\text{ mg/dL}, Phosphorus 5.8 mg/dL5.8\text{ mg/dL}, Intact PTH 450 pg/mL450\text{ pg/mL}, 1,251,25-dihydroxyvitamin D 12 pg/mL12\text{ pg/mL}, Creatinine 3.8 mg/dL3.8\text{ mg/dL}
Calcium 12.8 mg/dL12.8\text{ mg/dL}, Phosphorus 2.1 mg/dL2.1\text{ mg/dL}, Intact PTH 8 pg/mL8\text{ pg/mL}, PTH-related peptide 85 pg/mL85\text{ pg/mL}
Calcium 10.9 mg/dL10.9\text{ mg/dL}, Phosphorus 2.5 mg/dL2.5\text{ mg/dL}, Intact PTH 75 pg/mL75\text{ pg/mL}, 24-hour urine calcium 45 mg/day45\text{ mg/day}
Calcium 8.1 mg/dL8.1\text{ mg/dL}, Phosphorus 2.1 mg/dL2.1\text{ mg/dL}, Intact PTH 210 pg/mL210\text{ pg/mL}, 25-hydroxyvitamin D 8 ng/mL8\text{ ng/mL}

Matches

Show answer & explanation

Answer

The laboratory patterns uniquely correspond to autonomous PTH production (Primary hyperparathyroidism), renal failure with impaired vitamin D activation (CKD-MBD), ectopic PTHrP production (Humoral hypercalcemia of malignancy), altered calcium sensing (Familial hypocalciuric hypercalcemia), and deficient substrate for active vitamin D (Severe nutritional vitamin D deficiency).
Each specific combination of serum calcium, phosphorus, PTH, and supplementary markers uniquely identifies the locus of pathology in calcium homeostasis. High calcium with high PTH and hypercalciuria is the hallmark of primary hyperparathyroidism. Conversely, high calcium with high PTH but hypocalciuria defines FHH. High calcium with suppressed PTH but elevated PTHrP confirms HHM. In hypocalcemic states, a high phosphorus indicates renal failure (CKD-MBD), whereas a low phosphorus with low 25-hydroxyvitamin D confirms nutritional vitamin D deficiency.

Step-by-Step Solution

1
Evaluate the serum calcium and intact PTH levels to categorize the primary disturbance.
Identifies PTH-dependent hypercalcemia (high Ca, high PTH), PTH-independent hypercalcemia (high Ca, low PTH), or secondary hyperparathyroidism (low/normal Ca, high PTH).
This fundamental division narrows the differential diagnosis immediately.
2
Analyze phosphorus levels in the context of the PTH-calcium axis.
Low phosphorus with high PTH confirms PTH-mediated phosphate wasting (Primary hyperparathyroidism, Vitamin D deficiency). High phosphorus with high PTH suggests impaired renal excretion (CKD-MBD).
Phosphorus homeostasis differentiates primary renal failure from isolated PTH or Vitamin D abnormalities.
3
Utilize specific secondary markers (24-hour urine calcium, PTHrP, 25-OH Vitamin D) to confirm the exact etiology.
Differentiates Primary hyperparathyroidism (high urine Ca) from FHH (low urine Ca); confirms HHM via PTHrP; and distinguishes Vitamin D deficiency from CKD.
These specific markers isolate the pathophysiological root cause when the primary calcium-PTH axis shows similar patterns.

Key Concept

Interpretation of the calcium, phosphorus, parathyroid hormone, and vitamin D axes to diagnose specific metabolic bone and mineral disorders.
Question 1414Question →

Match the following glomerular diseases with their classic renal biopsy or immunofluorescence findings.

Click a left item, then click its matching right item

Items

Minimal change disease
Membranous nephropathy
IgA nephropathy
Goodpasture syndrome

Matches

Show answer & explanation

Answer

Minimal change disease pairs with podocyte effacement; Membranous nephropathy pairs with subepithelial 'spike and dome' deposits; IgA nephropathy pairs with mesangial immune complex deposits; and Goodpasture syndrome pairs with linear immunoglobulin deposition.
Each glomerular disease has a pathognomonic finding on biopsy. Minimal change disease requires electron microscopy to see podocyte effacement. Membranous nephropathy shows subepithelial 'spike and dome' deposits. IgA nephropathy localizes to the mesangium. Goodpasture syndrome is distinguished by linear anti-GBM antibody deposition.

Step-by-Step Solution

1
Analyze the histopathology of Minimal change disease.
Matches with diffuse effacement of podocyte foot processes.
It is the most common cause of pediatric nephrotic syndrome and lacks visible immune complex deposition.
2
Analyze the histopathology of Membranous nephropathy.
Matches with thickened capillary loops and subepithelial 'spike and dome' deposits.
Immune complexes deposit below the podocytes, prompting basement membrane material to grow up around them (spikes).
3
Analyze the histopathology of IgA nephropathy.
Matches with granular mesangial immune complex deposits.
IgA-based immune complexes specifically target and deposit within the mesangium, often following mucosal infections.
4
Analyze the histopathology of Goodpasture syndrome.
Matches with linear immunoglobulin deposition along the glomerular basement membrane.
Direct antibodies against the basement membrane (anti-GBM) coat the membrane smoothly, rather than in granular clumps.

Key Concept

Glomerular Disease Histopathology and Immunofluorescence Patterns
Estimated Time:1m 0s
Question 1415Question →

A 3535-year-old man who recently emigrated from a country with high tuberculosis endemicity presents to the emergency department. He reports a 66-week history of a persistent, blood-tinged cough, subjective fevers, drenching night sweats, and a 66-kg (1313-lb) weight loss. While in the crowded triage area, he is actively coughing. His vital signs show a temperature of 38.2∘C38.2^\circ\text{C} (100.8∘F100.8^\circ\text{F}). Arrange the following steps in the most appropriate chronological order for the optimal management of this patient.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence of actions is to first establish airborne infection isolation, followed by initial diagnostic imaging with a chest radiograph, then obtaining definitive microbiological sputum samples, and finally initiating multidrug antituberculous therapy.
The management of suspected active pulmonary tuberculosis follows a strict chronological progression prioritizing public health, then diagnosis, then treatment. The immediate placement of a surgical mask and transfer to an airborne infection isolation room prevents nosocomial transmission. Once isolated, a chest radiograph serves as the initial diagnostic step to quickly evaluate for typical cavitary or infiltrative disease. Following this, consecutive sputum samples for AFB smear and culture must be obtained to confirm the diagnosis and secure isolates for susceptibility testing. Finally, a four-drug treatment regimen is initiated only after all diagnostic samples are successfully collected.

Step-by-Step Solution

1
Prioritize infection control by placing a mask on the patient and moving them to a negative-pressure isolation room.
Prevents the aerosolized spread of Mycobacterium tuberculosis to other patients and healthcare staff.
Airborne transmission risk is highest when an untreated patient is actively coughing in a shared space.
2
Perform initial diagnostic imaging with a chest radiograph.
Evaluates for classic signs of primary or reactivation tuberculosis, such as upper lobe infiltrates or cavitary lesions.
Provides rapid supportive evidence for the clinical suspicion before waiting for lengthy laboratory tests.
3
Collect 33 consecutive sputum samples for AFB smear and culture.
Secures the biological samples needed for definitive microbiological diagnosis and eventual drug susceptibility testing.
Samples must be collected prior to initiating antibiotics to ensure the highest diagnostic yield.
4
Initiate a four-drug empiric therapy regimen.
Begins the lengthy process of eradicating the mycobacterial infection.
Pharmacotherapy is the definitive treatment but should only be started after isolation and appropriate diagnostic sampling.

Key Concept

In patients with suspected active pulmonary tuberculosis, strict airborne infection control (masking and negative-pressure isolation) is the absolute first step in management, preceding all diagnostic testing and therapeutic interventions.
Estimated Time:45s
Question 1416Question →

A 45-year-old man with a history of intravenous drug use presents to the emergency department with a 1-week history of high fevers, chills, and profound fatigue. His temperature is 39.2°C (102.6°F), blood pressure is 110/70 mm Hg, and heart rate is 115/min. Physical examination is notable for a new early diastolic murmur heard best at the left lower sternal border, and painless erythematous macules on the palms of his hands. Laboratory results show a leukocyte count of 18,000/mm³ with a left shift. Arrange the following diagnostic and therapeutic steps in the most appropriate chronological order for managing this patient's acute presentation.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is to first obtain blood cultures, then initiate empiric antibiotics, followed by a transthoracic echocardiogram, and finally a transesophageal echocardiogram if needed.
The management of acute infective endocarditis requires rapid and sequential action. Blood cultures are the most critical diagnostic step and must be drawn first to ensure pathogen identification. Because acute endocarditis can be rapidly fatal, empiric broad-spectrum antibiotics must be started immediately following the blood draw, before imaging confirms the diagnosis. Once therapy is initiated, a transthoracic echocardiogram (TTE) is performed as the initial imaging modality due to its non-invasive nature and wide availability. If the TTE is negative or technically limited (which is common for small vegetations), a transesophageal echocardiogram (TEE) is the definitive next step due to its superior sensitivity.

Step-by-Step Solution

1
Identify the primary clinical syndrome.
The patient presents with fever, a new murmur (suggestive of aortic regurgitation), and Janeway lesions, which is highly suspicious for acute infective endocarditis.
Recognizing the acute, potentially life-threatening nature of the infection dictates the urgency of the management sequence.
2
Determine the first critical diagnostic intervention.
Multiple sets of blood cultures must be obtained before any other action.
Administering antibiotics prior to drawing cultures drastically reduces the chance of isolating the pathogen, which is required for tailoring targeted antimicrobial therapy.
3
Determine the timing of pharmacologic therapy.
Empiric antibiotics (e.g., vancomycin to cover MRSA) are administered immediately after cultures are drawn.
Delaying antimicrobial therapy in acute endocarditis can lead to rapid valvular destruction, heart failure, or severe septic embolization.
4
Sequence the imaging modalities.
TTE is ordered first, followed by TEE if the TTE is negative.
TTE is non-invasive and highly specific, making it the appropriate initial test. TEE is more invasive but more sensitive, used as a step-up diagnostic tool when initial imaging is indeterminate.

Key Concept

In patients with suspected acute infective endocarditis, the critical management sequence is to draw multiple blood cultures first, immediately start broad-spectrum empiric antibiotics, and then proceed with echocardiographic imaging (TTE followed by TEE if necessary).
Estimated Time:1m 30s
Question 1417Question →

A 68-year-old man is brought to the emergency department with 3 days of severe, watery diarrhea and poor oral intake. He reports feeling lightheaded upon standing. His temperature is 37.1∘37.1^\circ C (98.8∘98.8^\circ F), blood pressure is 112/72112/72 mm Hg supine and 90/6090/60 mm Hg standing, and pulse is 92/min supine and 116/min standing. Physical examination reveals dry mucous membranes and delayed capillary refill.

Laboratory results are as follows:

Serum studies:
Sodium: 140140 mEq/L
Potassium: 3.53.5 mEq/L
Chloride: 110110 mEq/L
Bicarbonate: 2020 mEq/L
Blood urea nitrogen: 4242 mg/dL
Creatinine: 1.41.4 mg/dL

Urine studies:
Sodium: 2020 mEq/L
Creatinine: 4040 mg/dL

Based on these findings, what is the patient's fractional excretion of sodium?

Show answer & explanation

Answer: 0.5

Answer

0.5
The correct calculation of the Fractional Excretion of Sodium (FENa) requires the formula: FENa=UNa×PCrPNa×UCr×100FENa = \frac{U_{Na} \times P_{Cr}}{P_{Na} \times U_{Cr}} \times 100. Plugging in the patient's values yields (20×1.4)/(140×40)×100(20 \times 1.4) / (140 \times 40) \times 100, which simplifies to 28/5600×100=0.5%28 / 5600 \times 100 = 0.5\%. In the context of this patient's severe diarrhea, poor oral intake, and orthostatic hypotension, a FENa <1%< 1\% accurately supports the diagnosis of a prerenal state (hypovolemia) with an appropriate, intact renal tubular reabsorption of sodium.

Step-by-Step Solution

1
Identify the formula for Fractional Excretion of Sodium (FENa).
FENa=UNa×PCrPNa×UCr×100FENa = \frac{U_{Na} \times P_{Cr}}{P_{Na} \times U_{Cr}} \times 100
This formula is used to differentiate prerenal acute kidney injury from intrinsic renal disease by measuring the fraction of filtered sodium that is excreted.
2
Substitute the patient's laboratory values into the equation.
UNa=20U_{Na} = 20 mEq/L, PCr=1.4P_{Cr} = 1.4 mg/dL, PNa=140P_{Na} = 140 mEq/L, UCr=40U_{Cr} = 40 mg/dL
Accurate variable placement is required for correct calculation.
3
Calculate the final percentage.
(20×1.4)/(140×40)×100=(28/5600)×100=0.5%(20 \times 1.4) / (140 \times 40) \times 100 = (28 / 5600) \times 100 = 0.5\%
Mathematical simplification yields the final FENa percentage.

Key Concept

Calculation of Fractional Excretion of Sodium (FENa)
Question 1418Question →

A 71-year-old man is evaluated in the intensive care unit regarding his antimicrobial regimen. He was admitted 12 days ago for acute respiratory distress syndrome secondary to a severe viral pneumonitis and required endotracheal intubation. Five days ago, his clinical status deteriorated with the development of a fever up to 39.4°C (102.9°F), worsening hypoxia, and thick, purulent endotracheal secretions. A chest radiograph at that time demonstrated a new dense consolidation in the left lower lobe. Empiric intravenous therapy with piperacillin-tazobactam, tobramycin, and vancomycin was initiated.

Today, the patient is clinically improving; he is afebrile (37.1°C [98.8°F]), and his ventilator settings have been significantly weaned. The quantitative bronchoalveolar lavage culture obtained five days ago exhibits heavy growth (10510^5 CFU/mL) of *Pseudomonas aeruginosa*. Antimicrobial susceptibility testing indicates the organism is susceptible to piperacillin-tazobactam, cefepime, and ciprofloxacin, but resistant to tobramycin. No other organisms, including methicillin-resistant *Staphylococcus aureus* (MRSA), have been isolated. Blood cultures show no growth.

Which of the following is the most appropriate next step in this patient's pharmacotherapy?

Show answer & explanation

Answer: Discontinue tobramycin and vancomycin, and continue piperacillin-tazobactam monotherapy

Answer

Discontinue tobramycin and vancomycin, and continue piperacillin-tazobactam monotherapy.
The correct approach for this patient is to discontinue both tobramycin and vancomycin, continuing only piperacillin-tazobactam. The fundamental principle of antimicrobial stewardship in ventilator-associated pneumonia (VAP) is to initiate broad empiric therapy but de-escalate as soon as culture and susceptibility data are available. Because quantitative cultures did not yield MRSA, vancomycin must be stopped to reduce nephrotoxicity risk. Although empiric dual coverage for *Pseudomonas aeruginosa* (e.g., a beta-lactam plus an aminoglycoside) is appropriate to ensure initial activity against potentially resistant isolates, definitive therapy should be narrowed to a single active beta-lactam once susceptibilities are confirmed, provided the patient is not in septic shock. Piperacillin-tazobactam alone is fully active against this isolate and is sufficient for definitive cure.

Step-by-Step Solution

1
Evaluate the need for continued methicillin-resistant Staphylococcus aureus (MRSA) coverage.
The respiratory cultures did not grow MRSA.
Empiric MRSA coverage (vancomycin) should be discontinued if cultures are negative, in accordance with antimicrobial stewardship principles.
2
Assess the requirement for dual anti-pseudomonal therapy.
The patient's isolate is susceptible to piperacillin-tazobactam, and he is clinically improving.
Dual therapy is recommended for empiric coverage of suspected Pseudomonas infection to increase the likelihood of administering at least one active agent. Once susceptibilities are confirmed, definitive therapy with a single active beta-lactam is indicated.
3
Select the appropriate definitive regimen.
Discontinue tobramycin and vancomycin, retaining piperacillin-tazobactam.
Piperacillin-tazobactam provides adequate targeted monotherapy against this susceptible isolate while minimizing toxicity and resistance pressure.

Key Concept

In the management of ventilator-associated pneumonia, once pathogen susceptibilities are identified and the patient shows clinical improvement, empiric broad-spectrum therapy should be de-escalated. This includes stopping MRSA coverage if no MRSA is isolated and narrowing dual anti-pseudomonal therapy to a single active beta-lactam agent.
Question 1419Question →

A 58-year-old male is evaluated in the emergency department after his family noted progressive lethargy and confusion. According to his wife, he has experienced severe, nonbloody, bilious vomiting for the past five days. He has been unable to tolerate oral intake and has had minimal urine output for the past 24 hours. His medical history includes hypertension and untreated peptic ulcer disease. On physical examination, blood pressure is 88/54 mm Hg88/54 \text{ mm Hg}, and pulse is 118/min118/\text{min}. The patient appears lethargic. Mucous membranes are extremely dry, and skin turgor is significantly decreased.

Laboratory studies show the following:
Sodium: 140 mEq/L140 \text{ mEq/L}
Potassium: 3.2 mEq/L3.2 \text{ mEq/L}
Chloride: 90 mEq/L90 \text{ mEq/L}
Bicarbonate: 25 mEq/L25 \text{ mEq/L}
Blood urea nitrogen: 72 mg/dL72 \text{ mg/dL}
Creatinine: 3.4 mg/dL3.4 \text{ mg/dL}
Lactate: 6.2 mmol/L6.2 \text{ mmol/L}

Arterial blood gas (room air):
pH: 7.377.37
pCO2pCO_2: 45 mm Hg45 \text{ mm Hg}
pO2pO_2: 88 mm Hg88 \text{ mm Hg}

Which of the following best describes this patient's underlying acid-base derangements?

Show answer & explanation

Answer: Mixed high anion gap metabolic acidosis and metabolic alkalosis

Answer

Mixed high anion gap metabolic acidosis and metabolic alkalosis
This patient has a mixed high anion gap metabolic acidosis (HAGMA) and metabolic alkalosis. Despite a near-normal pH (7.377.37) and bicarbonate (25 mEq/L25 \text{ mEq/L}), calculating the anion gap reveals a value of 25 mEq/L25 \text{ mEq/L} (140−[90+25]140 - [90 + 25]), which confirms a HAGMA due to lactic acidosis (hypoperfusion) and uremia (acute kidney injury). To check for additional metabolic disorders, the delta-delta must be applied. The ΔAG\Delta AG is 1313 (25−1225 - 12). In a pure HAGMA, the bicarbonate should drop by this same amount, resulting in an expected bicarbonate of 11 mEq/L11 \text{ mEq/L} (24−1324 - 13). However, the patient's actual bicarbonate is 25 mEq/L25 \text{ mEq/L}. Because the actual bicarbonate is significantly higher than expected, there is a concurrent primary metabolic alkalosis, driven by the loss of gastric acid from severe vomiting. Finally, Winter's formula (1.5×25+8±2=45.5±21.5 \times 25 + 8 \pm 2 = 45.5 \pm 2) demonstrates that the patient's pCO2pCO_2 of 45 mm Hg45 \text{ mm Hg} is appropriate compensation, ruling out any respiratory acid-base disorder.

Step-by-Step Solution

1
Calculate the Anion Gap (AG) to identify the presence of a primary metabolic acidosis.
AG=Na+−(Cl−+HCO3−)=140−(90+25)=25 mEq/LAG = Na^+ - (Cl^- + HCO_3^-) = 140 - (90 + 25) = 25 \text{ mEq/L}.
Always calculate the AG even if the pH and bicarbonate appear near-normal, as opposing disorders can mask the derangement.
2
Calculate the Delta Gap (ΔAG\Delta AG) to determine how much the anion gap has risen above baseline.
ΔAG=Current AG−Normal AG=25−12=13 mEq/L\Delta AG = \text{Current AG} - \text{Normal AG} = 25 - 12 = 13 \text{ mEq/L}.
This value represents the amount of unmeasured acid added to the blood, which should theoretically lower the bicarbonate by the same amount.
3
Calculate the expected bicarbonate if the high anion gap metabolic acidosis (HAGMA) were the only disorder.
Expected HCO3−=24−ΔAG=24−13=11 mEq/L\text{Expected } HCO_3^- = 24 - \Delta AG = 24 - 13 = 11 \text{ mEq/L}. Since the actual HCO3−HCO_3^- is 25 mEq/L25 \text{ mEq/L}, which is much higher than 11 mEq/L11 \text{ mEq/L}, a concurrent Metabolic Alkalosis is present.
Comparing expected to actual bicarbonate (the delta-delta method) unmasks hidden secondary metabolic disorders.
4
Assess respiratory compensation using Winter's formula based on the actual measured bicarbonate.
Expected pCO2=1.5×(25)+8±2=45.5±2 mm Hg\text{Expected } pCO_2 = 1.5 \times (25) + 8 \pm 2 = 45.5 \pm 2 \text{ mm Hg}. The actual pCO2pCO_2 is 45 mm Hg45 \text{ mm Hg}, which falls within this range.
This confirms that there is no concurrent primary respiratory disorder; the respiratory status is perfectly compensated for the net bicarbonate level.

Key Concept

Delta-delta gap calculation unmasks hidden mixed acid-base disorders when opposing primary conditions (like lactic acidosis and vomiting) result in a deceptively normal pH or bicarbonate.
Estimated Time:2m 0s
Question 1420Question →

A 28-year-old woman, G1P0 at 3030 weeks gestation, comes to the clinic for a routine prenatal follow-up. She has a 5-year history of systemic lupus erythematosus (SLE) that has been quiescent on hydroxychloroquine. She reports mild, generalized fatigue and occasionally feeling "out of breath" when climbing stairs, but she explicitly denies joint pain, facial rashes, fevers, or chest pain. Her blood pressure is 112/70 mm Hg112/70 \text{ mm Hg}, and her pulse is 85/min85/\text{min}. Physical examination shows trace bilateral pedal edema but is otherwise unremarkable. Fetal heart tones are 145/min145/\text{min}.

Laboratory studies show the following:

TestResult
Hemoglobin10.2 g/dL10.2 \text{ g/dL}
Leukocyte count11,500/mm311,500/\text{mm}^3
Platelet count180,000/mm3180,000/\text{mm}^3
Serum creatinine0.6 mg/dL0.6 \text{ mg/dL}
Anti-dsDNA antibodiesNegative
Complement C3 and C4Normal

Arterial blood gas analysis on room air reveals:

ParameterResult
pH7.447.44
PaCO2_228 mm Hg28 \text{ mm Hg}
HCO3−_3^-19 mEq/L19 \text{ mEq/L}

Urinalysis shows trace protein with no red blood cells or cellular casts. The patient is anxious and asks if her recent symptoms and laboratory abnormalities indicate that her autoimmune disease is worsening. Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Continuation of current management and reassurance

Answer

Continuation of current management and reassurance
The correct approach is to continue current management and provide reassurance. This patient's symptoms (mild fatigue, occasional dyspnea) and laboratory findings (hemoglobin of 10.2 g/dL10.2 \text{ g/dL}, leukocyte count of 11,500/mm311,500/\text{mm}^3, and a compensated respiratory alkalosis) are hallmark, normal physiologic adaptations to pregnancy. Her systemic lupus erythematosus (SLE) remains clinically and serologically inactive, as strongly evidenced by her normal complement levels, negative anti-dsDNA antibodies, and the absence of active urinary sediment (e.g., no red blood cell casts or significant proteinuria). Hydroxychloroquine is safe during pregnancy and is highly recommended to maintain disease remission and improve fetal outcomes.

Step-by-Step Solution

1
Evaluate the clinical presentation and laboratory findings in the context of the third trimester of pregnancy.
The patient exhibits mild fatigue, trace pedal edema, dilutional anemia (hemoglobin 10.2 g/dL10.2 \text{ g/dL}), mild leukocytosis (11,500/mm311,500/\text{mm}^3), and a fully compensated respiratory alkalosis.
Pregnancy induces profound physiologic adaptations, including expanded plasma volume (causing dilutional anemia), progesterone-driven hyperventilation (causing chronic respiratory alkalosis with a compensatory drop in bicarbonate), and benign leukocytosis.
2
Assess the status of the patient's systemic lupus erythematosus (SLE) to rule out an acute disease flare.
The SLE is clinically and serologically quiescent. There are no active systemic symptoms, complement levels are normal, anti-dsDNA is negative, and the urinalysis is bland.
An active SLE flare in pregnancy would typically present with worsening proteinuria, hypertension, falling C3/C4 complement levels, and rising anti-dsDNA titers, none of which are present.
3
Determine the most appropriate management based on the findings.
The patient requires reassurance and continuation of her current hydroxychloroquine regimen.
Since all findings point to a normal, healthy pregnancy and well-controlled SLE, no acute interventions (such as steroids or diuretics) are indicated. Hydroxychloroquine should be maintained to prevent future flares.

Key Concept

Differentiating normal physiologic adaptations of pregnancy from acute systemic lupus erythematosus (SLE) flares
PreviousPage 71 / 158Next
Internal Medicine Practice Questions — USMLE Step 2 CK — Page 71 | Examkin